secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2024-10-08T23:59:59+00:00
Accession:  0001193125-24-234487
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 2.01, 3.02, 9.01, 3.03, 5.01, 5.02, 5.03, 5.05, 5.06, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

OnKure completes reverse merger with Reneo; trades as OKUR with $65M PIPE
-------------------------------------------------------------------------

- Reneo acquired OnKure in reverse merger; each OnKure common share exchanged for 0.023596 Class A shares.
- PIPE investors subscribed for $65M, receiving 2,839,005 Class A shares; total Class A outstanding ~12.65M.
- Reverse stock split 1:10, name change to OnKure Therapeutics, ticker changes from RPHM to OKUR.
- Lead candidate OKI-219 (PI3Kα H1047R inhibitor) in Phase 1; early data expected Q4 2024.
- New board and management: Nicholas Saccomano CEO, Samuel Agresta CMO, Jason Leverone CFO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/0001193125-24-234487-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/d836681d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-234487

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer